Sfrp2 and Cardiac Progenitor Cells in Regenerative Response to Ischemic Injury

Sfrp2 和心脏祖细胞对缺血性损伤的再生反应

• 批准号: 8403716
• 负责人: Victor J Dzau
• 金额: $ 41.63万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-15 至 2015-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8403716
• 关键词: Acute; Address; Adult; Apoptosis; Applications Grants; Biochemical; Biological Models; Biology; Cardiac; Cardiac Myocytes; Cardiovascular system; Cell Lineage; Cell Proliferation; Cells; Commit; Data; Development; Excision; Failure; Felis catus; Fibrosis; Future; Galactosidase; Genetic; Genomics; Heart; Heart failure; Hypertrophy; In Vitro; Infarction; Injection of therapeutic agent; Injury; Label; Laboratories; Lead; Maps; Mediating; Mediator of activation protein; Monitor; Mus; Muscle Cells; Myocardial; Myocardial Infarction; Myocardium; Natural regeneration; Nature; Pathway interactions; Patients; Pharmaceutical Preparations; Phase; Process; Proteins; Proto-Oncogene Protein c-kit; Protocols documentation; Regenerative Medicine; Regulation; Reporter; Research Proposals; Role; Signal Pathway; Signal Transduction; Staging; Stem cell transplant; Stem cells; Tamoxifen; Testing; Therapeutic; Tomatoes; Transgenic Mice; Transgenic Organisms; Troponin T; Wound Healing; angiogenesis; human SFRP4 protein; in vivo; in vivo regeneration; inhibitor/antagonist; insight; mortality; novel; novel therapeutics; progenitor; promoter; regenerative; repaired; response; stem cell differentiation

Several studies have suggested that Secreted Frizzled-related protein 2 (Sfrp2), a Wnt pathway inhibitor, is a key mediator of myocardial wound repair and has been shown to inhibit myocyte apoptosis, induce angiogenesis and inhibit fibrosis. In several model systems, Sfrp2 is a regulator of differentiation yet no studies have been performed that directly address the significance of Sfpr2 in cardiomyocyte renewal and the role of Sfpr2 in cardiac progenitor cell (CPC) activation, proliferation and differentiation remains to be elucidated. The regulation of CPC expansion and differentiation is a fundamental but yet unclear aspect of cardiovascular biology and regenerative medicine. Our preliminary studies, both in vitro and in vivo, suggest CPCs are responsive to Wnt/Sfrp2 signaling. Our data suggest that Sfrp2 inhibits canonical Wnt3a signaling and enhances differentiation in adult c-Kit+/Sca1+ CPCs. Thus, the role of the Sfrp2 in modulation of adult cardiomyocyte renewal by a potential Sfpr2/Wnt interaction poses an intriguing question. To address this, we hypothesize that Sfrp2, by modulating Wnt canonical pathway, is a key regulator of cardiac progenitor proliferation and lineage specification. To test this hypothesis, using cultured CPCs, we will investigate in vitro the importance of Sfpr2 and Wnt3a on CPC proliferation and differentiation, and elucidate the role of the Wnt/b-catenin canonical signaling pathway. In vivo, we will extend these studies by evaluating the role of Sfrp2 on cardiomyocyte renewal by examining its effects on endogenous CPC fate. We will use a genetic fate-mapping study and lineage tracing protocols to examine the proliferation and activation of endogenous cardiac stem cells, the differentiation of these cells to cardiac mocytes and determine the role of Sfrp2 on these processes and we will enquire about the importance of the Wnt/b-catenin canonical signaling pathway in mediating the Sfrp2 effects on CPCs in vivo. At the conclusion of this research proposal we will have characterized the role of Sfrp2 signaling in adult cardiac stem cells providing novel insights about the pathways that regulate these cells and opening new opportunities about their modulation ex vivo or in vivo for therapeutic purposes.

Several studies have suggested that Secreted Frizzled-related protein 2 (Sfrp2), a Wnt pathway inhibitor, is a key mediator of myocardial wound repair and has been shown to inhibit myocyte apoptosis, induce angiogenesis and inhibit fibrosis. In several model systems, Sfrp2 is a regulator of differentiation yet no studies have been performed that directly address the significance of Sfpr2 in cardiomyocyte renewal and the role of Sfpr2 in cardiac progenitor cell (CPC) activation, proliferation and differentiation remains to be elucidated. The regulation of CPC expansion and differentiation is a fundamental but yet unclear aspect of cardiovascular biology and regenerative medicine. Our preliminary studies, both in vitro and in vivo, suggest CPCs are responsive to Wnt/Sfrp2 signaling. Our data suggest that Sfrp2 inhibits canonical Wnt3a signaling and enhances differentiation in adult c-Kit+/Sca1+ CPCs. Thus, the role of the Sfrp2 in modulation of adult cardiomyocyte renewal by a potential Sfpr2/Wnt interaction poses an intriguing question. To address this, we hypothesize that Sfrp2, by modulating Wnt canonical pathway, is a key regulator of cardiac progenitor proliferation and lineage specification. To test this hypothesis, using cultured CPCs, we will investigate in vitro the importance of Sfpr2 and Wnt3a on CPC proliferation and differentiation, and elucidate the role of the Wnt/b-catenin canonical signaling pathway. In vivo, we will extend these studies by evaluating the role of Sfrp2 on cardiomyocyte renewal by examining its effects on endogenous CPC fate. We will use a genetic fate-mapping study and lineage tracing protocols to examine the proliferation and activation of endogenous cardiac stem cells, the differentiation of these cells to cardiac mocytes and determine the role of Sfrp2 on these processes and we will enquire about the importance of the Wnt/b-catenin canonical signaling pathway in mediating the Sfrp2 effects on CPCs in vivo. At the conclusion of this research proposal we will have characterized the role of Sfrp2 signaling in adult cardiac stem cells providing novel insights about the pathways that regulate these cells and opening new opportunities about their modulation ex vivo or in vivo for therapeutic purposes.